IBM began selling Watson to recommend the best cancer treatments to doctors around the world three years ago. But is it really doing its job? Not so much. An investigation by Stat found that the supercomputer isn't living up to the lofty expectations IBM created for it. It is still struggling with the basic step of learning about different forms of cancer. Only a few dozen hospitals have adopted the system, which is a long way from IBM's goal of establishing dominance in a multibillion-dollar market. And at foreign hospitals, physicians complained its advice is biased toward American patients and methods of care. From the report: The interviews suggest that IBM, in its rush to bolster flagging revenue, unleashed a product without fully assessing the challenges of deploying it in hospitals globally. While it has emphatically marketed Watson for cancer care, IBM hasn't published any scientific papers demonstrating how the technology affects physicians and patients. As a result, its flaws are getting exposed on the front lines of care by doctors and researchers who say that the system, while promising in some respects, remains undeveloped. [...] Perhaps the most stunning overreach is in the company's claim that Watson for Oncology, through artificial intelligence, can sift through reams of data to generate new insights and identify, as an IBM sales rep put it, "even new approaches" to cancer care. STAT found that the system doesn't create new knowledge and is artificially intelligent only in the most rudimentary sense of the term.
#NetNeutrality is STILL in danger - Click here to help. DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Check out the new SourceForge HTML5 Internet speed test. ×